ANI Pharmaceuticals sells former Oakville, ON manufacturing facility for C$19.2M (US$14.2M)

ANI PHARMACEUTICALS INC

Purchase price C$19.2M (~US$14.2M); buyer paid 5% deposit (~US$710k) with second 5% after due diligence.
Buyer has 5 business day due diligence period; closing expected by end of March 2024.
Sale includes land, building (~101,111 sq ft), chattels and fixtures; sold 'as is' with customary conditions.
ANI retains deposits if buyer defaults; deposits returned if ANI defaults or due diligence fails.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ANI PHARMACEUTICALS INC entered into Agreement with 1540700 Ontario Limited valued at $19,200,000 Canadian dollars (effective 2024-02-16).

Action: entry
Agreement: asset purchase
Counterparty: 1540700 Ontario Limited
Value: $19,200,000 Canadian dollars
Effective: 2024-02-16

Exact text from the filing

On February 16, 2024, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of ANI Pharmaceuticals, Inc. (“ANI”) entered into an agreement (the “Agreement”) with 1540700 Ontario Limited (“Buyer”) for the purchase and sale of ANI’s Oakville, Ontario former manufacturing facility (the “Property”) at a total purchase price of $19,200,000 Canadian dollars

View on SEC.gov

Browse all material agreements →

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001023024-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.